Hypertension pharmacogenomics

Pharmacogenomics And Hypertension: Current Insights - PMC

In this article, we carried out a comprehensive review of recent findings on the pharmacogenomics of antihypertensive drugs.

Pharmacogenomics of Hypertension Treatment - PubMed

Hypertension is one of the strongest modifiable cardiovascular risk factors, affecting an increasing number of people worldwide.

Hypertension pharmacogenomics: in search of personalized ...

This Review summarizes the available literature on the most convincing genetic signals associated with antihypertensive drug responses and adverse ...

Pharmacogenomics of Hypertension: A Genome‐Wide, Placebo ...

We have carried out a genome‐wide analysis of responses of 4 different antihypertensive drugs using very carefully designed experimental ...

The Future of Pharmacogenetics in the Treatment of Hypertension

Pharmacogenetics research has found that multiple genetic variants have a modest influence on individual response to different antihypertensive medications.

Pharmacogenomics of Hypertension and Preeclampsia - Frontiers

In this perspective article, we present advances of considering the interactions among genetic polymorphisms of different candidate genes within pathways ...

Pharmacogenomics of Hypertension Treatment - MDPI

This article reviews the recent pharmacogenomics literature concerning the key classes of antihypertensive drugs currently in use.

Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study

We report changes in hypertension control after providing a panel of 11 pharmacogenomic predictors of antihypertensive response.

Advancing management of hypertension through pharmacogenomics

Conceptually, the goal of hypertension pharmacogenomics is to be able to utilize genetic information, along with other pertinent clinical or demographic data, ...

Pharmacogenomics of Hypertension in Africa: Paving the Way for a ...

Pharmacogenetics presents as an attractive approach for optimum management of hypertension in Africa.

Pharmacogenomics of amlodipine and hydrochlorothiazide therapy ...

Hypertension (HTN) often called the “silent killer” is defined as a recurrent systolic/diastolic Blood pressure (BP) higher than 140/90 mmHg. It ...

A Physiologic Approach to the Pharmacogenomics of Hypertension

This review explores the contribution of genetics to facilitate antihypertensive agent selection and predict treatment efficacy.

Pharmacogenomic approaches to study the effects of ... - Nature

Pharmacogenomic studies aim to clarify the role of various genes and their variations in relation to the effects of antihypertensive drugs.

Personalized antihypertensive treatment guided by ...

Pharmacogenomics-guided personalized treatment of hypertensive patients is likely to be a more effective strategy, especially in those with significantly ...

Pharmacogenomics of Hypertension Treatment - Semantic Scholar

The results of numerous studies confirm that genotype-based antihypertension therapies are the most effective and may help to avoid the occurrence of major ...

Pharmacogenomics considerations in the control of hypertension.

Discussed In Paper More information · Ace Inhibitors, Plain · Angiotensin II Antagonists · Beta Blocking Agents · Calcium channel blockers · diuretics ...

Pharmacogenomics and hypertension: Current insights

To address the effects of genetic polymorphisms on blood pressure responses to the antihypertensive drug classes, studies have applied candidate genes and ...

Hypertension pharmacogenomics: current status and future directions.

Hypertension pharmacogenomics holds tremendous potential for providing a mechanism by which management of hypertensive patients might be improved, ...

Pharmacogenomics of antihypertensive drugs

Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic. Evaluation of Antihypertensive Responses (PEAR) study. Julie A ...

Pharmacogenomics of Hypertension and Heart Disease

While limited clinically translatable data are available for β-blockers or aspirin, sufficient clinically relevant pharmacogenetic data exist ...